Prognosis of hospitalized patients with community-acquired pneumonia

Akyıl, Fatma Tokgöz; Yalçınsoy, Murat; Hazar, Armagan; Çilli, Aykut; Celenk, Burcu; Kilic, Oznur; Sayıner, Abdullah; Köktürk, Nurdan; Coşkun, Ayşın Şakar; Filiz, Ayten; Edis, Ebru Çakır

doi:10.1016/j.rppnen.2017.07.010

Cited by 32 publications

(16 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Elevated BUN levels are a predictor of worse outcome in patients with heart failure [7] . Recent studies have shown that the BUN to serum albumin ratio is an important prognostic factor of mortality and disease severity in aspiration pneumonia, hospital-acquired pneumonia and community-acquired pneumonia (CAP) [8] , [9] , [10] . Moreover, serum albumin levels were also identified as prognostic factors for pneumonia diseases and demonstrated fair discriminative performance in the prediction of in-hospital mortality [ 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Diagnostic performance of initial blood urea nitrogen combined with D-dimer levels for predicting in-hospital mortality in COVID-19 patients

Cheng

Wang

et al. 2020

International Journal of Antimicrobial Agents

108

View full text Add to dashboard Cite

Highlights Initial blood urea nitrogen (BUN) and D-dimer levels were associated with mortality in COVID-19 patients. Combination of BUN ≥ 4.6 mmol/L and D-dimer ≥ 0.845 μg/mL can identify patients at high risk of in-hospital mortality. Development of a nomogram model based on initial BUN and D-dimer levels. The nomogram could be a suitable and useful individualised tool to predict mortality in COVID-19 patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Diagnostic performance of initial blood urea nitrogen combined with D-dimer levels for predicting in-hospital mortality in COVID-19 patients

Cheng

Wang

et al. 2020

International Journal of Antimicrobial Agents

108

View full text Add to dashboard Cite

show abstract

“…This study further revealed that the non-survivors had signi cantly higher levels of BUN and lower levels of serum Alb than those in the survivors. In addition, high BUN and low serum Alb levels were poor prognostic factors for patients with CAP [13][14][15][16], and the BUN/Alb ratio was useful in predicting the mortality of patients with CAP [19,35]. Moreover, the BUN/Alb ratio was also a useful marker for predicting the mortality in patients with HAP and aspiration pneumonia [17,18].…”

Section: Discussionmentioning

confidence: 99%

A-DROP and Blood Urea Nitrogen-to-Serum Albumin Ratio are Useful in Assessing the Severity of Pneumocystis Pneumonia in Patients Without Human Immunodeficiency Virus Infection: A Retrospective Study

Akahane¹,

Ushiki²,

Kosaka³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: There is an increasing incidence of Pneumocystis pneumonia among individuals without the human immunodeficiency virus (HIV) infection (non-HIV Pneumocystis pneumonia). However, the prognostic factors for patients with non-HIV Pneumocystis pneumonia have not been identified. Moreover, A-DROP (for classifying the severity of community-acquired pneumonia) or the blood urea nitrogen-to-serum albumin ratio, which is reported to be predictor of mortality of community-acquired pneumonia, has not been established as an efficient prognostic factor in patients with non-HIV Pneumocystis pneumonia. In this study, we analyzed the prognostic factors for non-HIV Pneumocystis pneumonia and evaluated the effectiveness of A-DROP and the blood urea nitrogen-to-serum albumin ratio as prognostic factors.Methods: This retrospective study involved a chart review of the medical records of 102 patients diagnosed with non-HIV Pneumocystis pneumonia between January 2003 and May 2019 at five medical facilities. Prognostic factors associated with the 30-day mortality were assessed using multiple logistic regression analysis.Results: Among the 102 patients with non-HIV Pneumocystis pneumonia, 46 (45.1%) had autoimmune diseases, 19 (18.6%) had hematological malignancies, 18 (17.7%) had solid malignancies, and 19 (18.6%) had other diseases. The 30-day mortality rate for non-HIV Pneumocystis pneumonia was 20.5% in this study population. Compared with survivors, non-survivors had significantly lower serum albumin levels and a significantly higher age, corticosteroid dosage at the onset of Pneumocystis pneumonia, alveolar–arterial oxygen gradient, A-DROP score, lactate dehydrogenase levels, blood urea nitrogen levels, and blood urea nitrogen-to-serum albumin ratio. The results of multivariate analysis showed that a high A-DROP score and blood urea nitrogen-to-serum albumin ratio at treatment initiation were significantly associated with the 30-day mortality risk.Conclusions: A high A-DROP score and blood urea nitrogen-to-serum albumin ratio at treatment initiation are independent prognostic predictors of mortality risk in patients with non-HIV Pneumocystis pneumonia.

show abstract

“…We assume inpatient and outpatient CAP case fatality rates (CFRs) of 9.2% and 0%, respectively. 43 We derive bacteremia and meningitis CFRs using 2016 data from the ECDC Surveillance Atlas of Infectious Diseases for the above-mentioned six comparator countries. 38 See the Methodological Appendix for further details.…”

Section: Case Fatality and Disability Ratesmentioning

confidence: 99%

Indirect costs of adult pneumococcal disease and the productivity-based rate of return to the 13-valent pneumococcal conjugate vaccine for adults in Turkey

Sevilla

Stawasz

Burnes

et al. 2020

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Productivity benefits of health technologies are ignored in typical economic evaluations from a health payer's perspective, risking undervaluation. We conduct a productivity-based cost-benefit analysis from a societal perspective and estimate indirect costs of adult pneumococcal disease, vaccination benefits from the adult 13-valent pneumococcal conjugate vaccine (PCV13 Adult), and rates of return to PCV13 Adult for a range of hypothetical vaccination costs. Our context is Turkey's funding PCV13 for the elderly and for non-elderly adults with select comorbidities within the Ministry of Health's National Immunization Program. We use a Markov model with one-year cycles. Indirect costs from death or disability equal the expected present discounted value of lifetime losses in the infected individual's paid and unpaid work and in caregivers' paid work. Vaccination benefits comprise averted indirect costs. Rates of return equal vaccination benefits divided by vaccination costs, minus one. Input parameters are from public data sources. We model comorbidities' effects by scalar multiplication of the parameters of the general population. Indirect costs per treatment episode of inpatient community-acquired pneumonia (CAP), bacteremia, and meningitisbut not for outpatient CAPapproach or exceed Turkish per capita gross domestic product. Vaccination benefits equal $207.02 per vaccination in 2017 US dollars. The rate of return is positive for all hypothetical costs below this. Results are sensitive to herd effects from pediatric vaccination and vaccine efficacy rates. For a wide range of hypothetical vaccination costs, the rate of return compares favorably with those of other global development interventions with well-established strong investment cases.

show abstract

Prognosis of hospitalized patients with community-acquired pneumonia

Cited by 32 publications

References 25 publications

Diagnostic performance of initial blood urea nitrogen combined with D-dimer levels for predicting in-hospital mortality in COVID-19 patients

Diagnostic performance of initial blood urea nitrogen combined with D-dimer levels for predicting in-hospital mortality in COVID-19 patients

A-DROP and Blood Urea Nitrogen-to-Serum Albumin Ratio are Useful in Assessing the Severity of Pneumocystis Pneumonia in Patients Without Human Immunodeficiency Virus Infection: A Retrospective Study

Indirect costs of adult pneumococcal disease and the productivity-based rate of return to the 13-valent pneumococcal conjugate vaccine for adults in Turkey

Contact Info

Product

Resources

About